The future of medicine lies within us.
We are an in vivo hematopoietic stem cell (HSC) engineering company.
Ensoma’s platform revealed
We are creating a new kind of genomic medicine for patients around the world.
Our technology platform enables in vivo engineering of hematopoietic stem cells (HSCs). It combines an off-the-shelf in vivo delivery system with a state-of-the-art gene engineering toolkit. Our vision is for an HSC engineering platform that selectively and durably modifies cells of the hematopoietic system with the intent to treat diseases with unprecedented versatility – all with a one-time treatment regimen.
A vision for the treatment journey
The patient experience is a crucial part of treatment. We aim to shape a new experience defined by simplicity, speed and safety.
Excited by our bold vision to bring forth a new kind of medicine?
